About us
Our History
Transforming the Understanding and Treatment of Neurodegeneration
ImmunoBrain Checkpoint is a clinical-stage biopharmaceutical company committed to developing innovative immunotherapies for neurological disorders.
Protective Autoimmunity
Prof. Michal Schwartz suggests the concept of “Protective Autoimmunity”,
and that peripheral immune cells play a critical role in shaping brain function.
ImmunoBrain Checkpoint is founded
ImmunoBrain Checkpoint, Inc. incorporates and enters a Research and
License Agreement with Yeda, the commercialization company of the
Weizmann Institute of Science to develop and commercialize the technology
that emerges out of the Schwartz lab.
Immune checkpoint blockade
First evidence that immune checkpoint therapeutic approach can be utilized
for treating Alzheimer's disease (Baruch et al., 2016, Nature Medicine).
Lead selection and optimization
ImmunoBrain Checkpoint licenses the rights to develop and commercialize a
novel, fully human anti-PD-L1 antibody from Kymab (now a Sanofi company).
Regulatory approvals
Regulatory approvals received to initiate clinical study in Europe.
IBC-01-01 clinical study
ImmunoBrain Checkpoint initiates IBC-01-01 Trial, a randomized, double-blind,
placebo-controlled, first-in-human Phase Ib clinical trial in persons with
early Alzheimer’s disease.
